Part of the 2019 European equity crowdfunding campaign hosted on https://www.aescuvest.eu/projects/surge-on-medical/
Visit www.surge-on.eu for more information
International Business:MOST FAVOURED NATION (mfn) treatmentZaheer Sayyed
The Most Favored Nation (MFN) treatment is a status awarded by one nation to another in international trade that guarantees that nation will not be treated worse than any other nation. There are conditional and unconditional types of MFN treatment. MFN treatment benefits countries by allowing imports from the most efficient suppliers, protecting bilateral trade concessions, and restraining domestic protectionism. Key features of MFN treatment include being a treaty-based obligation governed by similar objective situations, not applying to special contracts, and ensuring equal treatment for foreign investors.
The Islamic financial industry adheres to Islamic principles and has existed for over 1,400 years. It broadly refers to financial transactions, operations, and services that comply with Islamic rules. Islamic finance has grown significantly in recent decades and the global market is expected to reach $3-4 trillion in the next 4-5 years. Islamic wealth management helps individuals accumulate wealth in ethical and halal ways, protect it through takaful rather than interest-based insurance, and distribute it according to Islamic inheritance rules or civil law for non-Muslims.
This document provides an overview of Riba (interest) in Islam. It begins with an introduction that establishes the key principles of the Islamic economic system, including justice, equality and prohibiting exploitation.
The document is divided into five parts. Part 1 discusses the Islamic ruling prohibiting Riba, providing evidence from the Quran and Hadith. Part 2 compares Islamic economics to other systems. Part 3 defines Riba linguistically and legally. Part 4 explains why Riba is haram both prophetically and rationally. Part 5 examines contemporary issues regarding Riba and credit cards.
The conclusion restates that Riba is considered unjust and illegal in Shariah as it exploits people's needs and creates inequality.
The International Monetary Fund (IMF) promotes global economic growth and financial stability. It provides loans to countries experiencing balance of payments problems to replenish international reserves and stabilize currencies. The IMF is governed by the Board of Governors consisting of all member states and has an Executive Board and Managing Director that handle daily operations. It offers several types of loans including Stand-By Arrangements for short-term assistance and Extended Fund Facility loans for medium-term support.
The document discusses Islamic banking principles and how it differs from conventional banking. It provides details on various Islamic banking concepts like profit and loss sharing, prohibition of riba or interest, and financing based on real assets. Some key Islamic banking contracts discussed include murabaha, istisna, bai muajjal, mudarabah, musharakah, and ijarah-wal-iqtina. While Islamic banking aims to align with Shariah principles, critics argue it resembles conventional banking by simply renaming interest. Implementation challenges also exist regarding monitoring costs and lack of unification among Islamic banks.
NISM Series VIII - Equity Derivatives Model PaperSunil Yadav
This document provides 10 sample questions from the NISM Series VIII - Equity Derivatives Certification Exam. It introduces the topic of the questions and provides the questions and multiple choice answers. It encourages the reader to visit an online site to find the answers and offers a demo test and full question bank for the exam for a fee.
The document discusses the territorial sea (TS) and its history. It defines TS as extending up to 12 nautical miles from a coastal state's baseline under UNCLOS. Conflicts can arise when states claim bodies of water as internal waters beyond the 12 nm limit. The document specifically examines conflicts in the Gulf of Sidra, where Libya claims the entire gulf but the US recognizes only Libya's 12 nm TS, leading to military incidents in 1981 and 1989 to assert freedom of navigation rights.
International Business:MOST FAVOURED NATION (mfn) treatmentZaheer Sayyed
The Most Favored Nation (MFN) treatment is a status awarded by one nation to another in international trade that guarantees that nation will not be treated worse than any other nation. There are conditional and unconditional types of MFN treatment. MFN treatment benefits countries by allowing imports from the most efficient suppliers, protecting bilateral trade concessions, and restraining domestic protectionism. Key features of MFN treatment include being a treaty-based obligation governed by similar objective situations, not applying to special contracts, and ensuring equal treatment for foreign investors.
The Islamic financial industry adheres to Islamic principles and has existed for over 1,400 years. It broadly refers to financial transactions, operations, and services that comply with Islamic rules. Islamic finance has grown significantly in recent decades and the global market is expected to reach $3-4 trillion in the next 4-5 years. Islamic wealth management helps individuals accumulate wealth in ethical and halal ways, protect it through takaful rather than interest-based insurance, and distribute it according to Islamic inheritance rules or civil law for non-Muslims.
This document provides an overview of Riba (interest) in Islam. It begins with an introduction that establishes the key principles of the Islamic economic system, including justice, equality and prohibiting exploitation.
The document is divided into five parts. Part 1 discusses the Islamic ruling prohibiting Riba, providing evidence from the Quran and Hadith. Part 2 compares Islamic economics to other systems. Part 3 defines Riba linguistically and legally. Part 4 explains why Riba is haram both prophetically and rationally. Part 5 examines contemporary issues regarding Riba and credit cards.
The conclusion restates that Riba is considered unjust and illegal in Shariah as it exploits people's needs and creates inequality.
The International Monetary Fund (IMF) promotes global economic growth and financial stability. It provides loans to countries experiencing balance of payments problems to replenish international reserves and stabilize currencies. The IMF is governed by the Board of Governors consisting of all member states and has an Executive Board and Managing Director that handle daily operations. It offers several types of loans including Stand-By Arrangements for short-term assistance and Extended Fund Facility loans for medium-term support.
The document discusses Islamic banking principles and how it differs from conventional banking. It provides details on various Islamic banking concepts like profit and loss sharing, prohibition of riba or interest, and financing based on real assets. Some key Islamic banking contracts discussed include murabaha, istisna, bai muajjal, mudarabah, musharakah, and ijarah-wal-iqtina. While Islamic banking aims to align with Shariah principles, critics argue it resembles conventional banking by simply renaming interest. Implementation challenges also exist regarding monitoring costs and lack of unification among Islamic banks.
NISM Series VIII - Equity Derivatives Model PaperSunil Yadav
This document provides 10 sample questions from the NISM Series VIII - Equity Derivatives Certification Exam. It introduces the topic of the questions and provides the questions and multiple choice answers. It encourages the reader to visit an online site to find the answers and offers a demo test and full question bank for the exam for a fee.
The document discusses the territorial sea (TS) and its history. It defines TS as extending up to 12 nautical miles from a coastal state's baseline under UNCLOS. Conflicts can arise when states claim bodies of water as internal waters beyond the 12 nm limit. The document specifically examines conflicts in the Gulf of Sidra, where Libya claims the entire gulf but the US recognizes only Libya's 12 nm TS, leading to military incidents in 1981 and 1989 to assert freedom of navigation rights.
X Sector Disruption | CIO Leaders Summit 2015 | The Propell GroupJulien de Salaberry
- Technology is or will disrupt your sector
- Hoping that it might miss you out is not a strategy!
- You will need to embrace and adopt the technology to innovate to stay in the game
- You also have the opportunity to explore how technology could enable your industry to disrupt another
The document discusses go-to-market strategies for product engineering services in the orthopedics sector. It provides an overview of the large and growing global orthopedics market and outsourcing industry. It then outlines the primary factors driving demand for consulting product engineering services in orthopedics. Some key opportunities identified include implant designing, orthopedics PACS systems, medical devices, software applications, product validation, and operating room solutions. The document recommends starting with orthopedics PACS to enter the market and also partnering with large western companies to bring navigation technologies to India.
The team conducted over 100 interviews with surgeons, radiologists, administrators and other stakeholders. Based on feedback, they pivoted their focus from urology to thoracic surgery. Thoracic surgeons expressed a strong need for a product that could help localize lung lesions minimally invasively. The team determined thoracic surgery represents a $250 million market opportunity in the US. They have refined their product and business model based on learning that thoracic surgeons could find small lung nodules twice as fast with the technology without need for preoperative preparation. The team believes they will pursue an SBIR Phase II application with a significant pivot in customer segments from original plans but that the technical feasibility remains.
Caduceus Medical Corp is developing non-invasive devices to monitor intraocular pressure and treat glaucoma and other eye conditions. Their first product, the IOP Sensor, continuously measures intraocular pressure over time to aid in earlier diagnosis and treatment. They have filed patents and plan to market to ophthalmologists and optometrists in the US initially. The management team has extensive experience in ophthalmic devices. They are seeking $14 million to complete development and clinical trials and launch the product.
With Piezomed, users can concentrate on the surgical procedure with a piece o...A-dec Australia
W&H's Piezomed device utilizes innovative ultrasound technology to facilitate precise and minimally invasive bone cutting for dental surgeons. It was developed to complement their existing surgical product range and addresses the need for a piezoelectric device. Significant research was required to develop it given the demanding precision required. The automatic instrument detection system and ability to precisely cut bone make it useful for a variety of dental procedures.
RD Medical is a company that designs and manufactures spinal fixation systems and implants. It was founded by mechanical and materials engineers, along with clinical experts. The company supplies innovative, high-quality products to the biomedical industry as an OEM partner. PRODORTH products are designed, manufactured, and developed in-house. The company aims to provide top-notch, detailed products to contribute to successful surgeries and patient outcomes. It works to satisfy the need for high-quality, fast-supplied products in the medical sector.
This document provides a business plan for SeamVad, a medical device company developing automated vascular anastomosis devices. SeamVad's flagship product, the MySide device, uses a connector and applicator to perform vessel anastomoses in a simple 6-step process, reducing time compared to manual suturing. The $3 billion global vascular devices market is poised for growth. SeamVad seeks $3 million in funding to complete clinical trials and gain CE Mark approval by 2014. The management team has extensive experience in vascular surgery and medical devices. The plan outlines SeamVad's product, the clinical need it addresses, competitive landscape, and financial projections.
Capsule Endoscopy Patent Landscape 2014 Sample
Olympus and Given Imaging are leading intellectual property in the capsule endoscopy industry, but for how long?
KEY FEATURES OF THE REPORT
The report provides essential patent data for capsule endoscopy. It identifies more than 30 major holders of capsule endoscopy related intellectual property. It provides in-depth IP analysis and industrial key players including:
-Time evolution of patent publications and countries of patent filings.
-Current legal status of patents.
-Ranking of main patent applicants.
-Joint developments and IP collaboration network of main patent applicants.
-Key patents.
-Granted patents near expiration.
-Relative strength of main companies IP portfolio.
-Overview of patent litigations.
-Matrix applicants/technology issues for more than 15+ companies.
The “capsule endoscopy IP” profiles of 15+ major companies is presented, with key patents, technological issues, litigations, licenses, partnerships, and IP strength and strategy.
The report also provides an extensive Excel database with all patents analyzed in the report.
OBJECTIVE OF THE REPORT
•Understand the IP landscape for capsule endoscopy.
•Identify key patents.
•Understand trends in capsule endoscopy IP.
•Identify the major players in capsule endoscopy IP and the relative strength of their patent portfolio.
•Identify new players in capsule endoscopy IP.
•Identify IP collaboration networks between key players (industrial and academics).
•Identify main patent litigations.
Top 5 Trends from RSNA 2015 Day 1 | MD BuylineMD Buyline
Day 1 of RSNA 2015: Learn what the top trends were at the Radiological Society of North America (RSNA) annual meeting and scientific assembly for 2015; from the leader in healthcare supply chain management solutions, MD Buyline.
For the full article, visit http://www.mdbuyline.com/research-library/articles/top-5-trends-from-rsna-2015-day-1/.
Europe’s Most Innovative Medical Device Companies of 2023 (Bleed) 2 (1).pdfinsightscare
This article profiles Morpheus AG, a medical device company focused on developing innovative surgical instruments. The company's flagship product is the Rebellion Bone Removal System, which allows surgeons to efficiently cut through bone while minimizing risks. Morpheus AG is dedicated to designing technologies that maximize safety, efficiency and effectiveness in the operating room. The company prioritizes innovation, quality and patient safety in its work. It aims to develop solutions that can help healthcare professionals and improve patient outcomes.
Capsule Endoscopy Patent Landscape Flyer 2014
Olympus and Given Imaging are leading intellectual property in the capsule endoscopy industry, but for how long?
KEY FEATURES OF THE REPORT
The report provides essential patent data for capsule endoscopy. It identifies more than 30 major holders of capsule endoscopy related intellectual property. It provides in-depth IP analysis and industrial key players including:
-Time evolution of patent publications and countries of patent filings.
-Current legal status of patents.
-Ranking of main patent applicants.
-Joint developments and IP collaboration network of main patent applicants.
-Key patents.
-Granted patents near expiration.
-Relative strength of main companies IP portfolio.
-Overview of patent litigations.
-Matrix applicants/technology issues for more than 15+ companies.
The “capsule endoscopy IP” profiles of 15+ major companies is presented, with key patents, technological issues, litigations, licenses, partnerships, and IP strength and strategy.
The report also provides an extensive Excel database with all patents analyzed in the report.
OBJECTIVE OF THE REPORT
•Understand the IP landscape for capsule endoscopy.
•Identify key patents.
•Understand trends in capsule endoscopy IP.
•Identify the major players in capsule
endoscopy IP and the relative strength of
their patent portfolio.
•Identify new players in capsule endoscopy IP.
•Identify IP collaboration networks between key players (industrial and academics).
•Identify main patent litigations.
Medvantage International has acquired rights to a new vascular coupling device called CUVASLAR that represents an alternative to manual suturing for connecting arteries and veins. The device is expected to reduce surgical time, minimize errors from suturing, and improve patient outcomes. Medvantage plans to submit the device for FDA approval over the next year and market it to the 340,000 microsurgery procedures performed annually in the US.
Anteo Technologies - New York presentation 2015Matt Sanderson
- Anteo Diagnostics is an Australian biotechnology company that develops proprietary surface coatings called Mix&Go for use in healthcare, life sciences, and other industries.
- Mix&Go is a universal double-sided molecular coating that gently but strongly binds biomolecules to synthetic surfaces, addressing challenges in test miniaturization and cost reduction.
- Anteo's growth strategy includes licensing its intellectual property, expanding its coating technologies and applications, developing product pipelines that demonstrate Mix&Go's uses, exploring new market opportunities, and acquiring synergistic assets.
Ultrasound Sensing Technologies for Medical, Industrial and Consumer Applicat...Yole Developpement
New applications along with manufacturing capabilities and technological readiness are driving the takeoff of micro-machined ultrasonic transducers.
More information on that report at https://www.i-micronews.com/category-listing/product/ultrasound-sensing-technologies-for-medical-industrial-and-consumer-applications.html
1) Terumo Corporation developed the world's thinnest insulin injection needle called the Nanopass 33 needle in collaboration with Okano company.
2) Terumo obtained patent protection for the needle's slim double tapered shape and asymmetric bevel which reduces pain during injections.
3) Terumo also registered its company trademark to protect its brand and product names.
Michael Alvers, Transinsight, DE (Fortissimo)I4MS_eu
The document discusses using high-performance computing (HPC) for drug-target binding simulations. It describes how HPC resources from the Fortissimo project enable performing over 450 million pairwise molecule-ligand comparisons, allowing for novel drug target prediction, side effect prediction, and drug repositioning. Two universities implemented and optimized distributed algorithms to run the drug binding simulations on HPC infrastructure 5-10 times faster. This provides a framework for previously impossible bioinformatics analyses to discover new drugs.
An NGO called mothers2mothers (m2m) recruits and trains HIV-positive mothers to provide support to other mothers living with HIV/AIDS. m2m has expanded across Africa and helps prevent mother-to-child transmission of HIV. The organization protects its brand identity through trademarks on its name and logo, which help promote public awareness and fundraising efforts. Trademarks provide affordable intellectual property protection that supports m2m's work in building its reputation.
This document provides background information for developing a launch plan for Monocryl Plus, a new antibacterial coated synthetic absorbable suture. It discusses the suture market challenges facing Ethicon, including increased competition from low-cost producers. It also reviews the product details and performance of existing sutures like Vicryl and Monocryl. The consultant has been asked to develop a strategic launch plan for Monocryl Plus to drive adoption among surgeons and in new applications/markets.
How well did Thaldorf interact with each member of the DMUOn what.pdfallystraders
How well did Thaldorf interact with each member of the DMU?
On what date did Thaldorf effectively lose the sale to Lohmann University? On December 18,
Kurt Thaldorf, a sales engineer for can diagnose cancer of the pancreas in less than two the
German sales subsidiary of Mediquip, S.A., was weeks after it develops. This was not possible
before informed by Lohmann University Hospital in Stuttgart CT scanners." that it had decided
to place an order with Sigma, a Mediquip was a subsidiary of Technologie UniDutch competitor,
for a CT scanner. The hospital's verselle, a French conglomerate. The company's proddecision
came as disappointing news to Thaldorf, who uct line included, in addition to CT scanners, X-
ray, had worked for nearly eight months on the account. ultrasonic, and nuclear diagnostic
equipment. Mediquip The order, if obtained, would have meant a sale of enjoyed a worldwide
reputation for advanced technol(Euro) 2,370,000 for the sales engineer. 1 He was con- ogy and
competent after-sales service. vinced that Mediquip's CTscanner was technologically "Our
competitors are mostly from other European superior to Sigma's and, overall, a better product.
countries," commented Mediquip's Sales Director for Thaldorf began a review of his call reports
in order Europe. "In some markets they have been there longer to better understand the factors
that had led to Lohmann than we have, and they know the decision-makers betUniversity
Hospital's decision. He wanted to apply the ter than we do. But we are learning fast." Sigma, the
lessons from this experience to future sales situations. subsidiary of a diversified Dutch company
under the same name, was the company's most serious competiBACKGROUND tor. Other
major contenders in the CT scanner market were FNC, Eldora, Magna, and Piper. At the time,
the computer tomography (CT) scanner Mediquip executives estimated the European marwas a
relatively recent product in the field of diagnostic ket for CT scanners to be around 200 units per
year. imaging. This medical device, used for diagnostic pur- They pointed out that prices ranged
from 1.5 to 3.0 poses, allowed examination of cross sections of the million per unit. The
company's CT scanner sold in the human body through display of images. CT scanners upper
end of the price range. "Our equipment is at least combined sophisticated X-ray equipment with
a com- two years ahead of our most advanced competition," puter to collect the necessary data
and translate them explained a sales executive. "And our price reflects this into visual images.
When computer tomography was first introduced in Mediquip's sales organization in Europe
included the late 1960s, radiologists had hailed it as a major tech- eight country sales
subsidiaries, each headed by a mannologiqal breakthrough. Commenting on the advantages
aging director. Within each country, sales engineers of CT scanners, a product specialist with
Mediquip said, reported to regional sales managers who, in turn, ".
Going into this situation, what were Thaldorf�s major strengths and .pdfaucmistry
Going into this situation, what were Thaldorfs major strengths and weaknesses as a
representative of Mediquip?
Identify each member of Lohmann Hospitals decision-making unit (DMU).
What were the needs, concerns, and motivation of each DMU member?
What was the relative power position of each DMU member? On December 18, Kurt Thaldorf, a
sales engineer for can diagnose cancer of the pancreas in less than two the German sales
subsidiary of Mediquip, S.A., was weeks after it develops. This was not possible before informed
by Lohmann University Hospital in Stuttgart CT scanners." that it had decided to place an order
with Sigma, a Mediquip was a subsidiary of Technologie UniDutch competitor, for a CT
scanner. The hospital's verselle, a French conglomerate. The company's proddecision came as
disappointing news to Thaldorf, who uct line included, in addition to CT scanners, X-ray, had
worked for nearly eight months on the account. ultrasonic, and nuclear diagnostic equipment.
Mediquip The order, if obtained, would have meant a sale of enjoyed a worldwide reputation for
advanced technol(Euro) 2,370,000 for the sales engineer. 1 He was con- ogy and competent
after-sales service. vinced that Mediquip's CTscanner was technologically "Our competitors are
mostly from other European superior to Sigma's and, overall, a better product. countries,"
commented Mediquip's Sales Director for Thaldorf began a review of his call reports in order
Europe. "In some markets they have been there longer to better understand the factors that had
led to Lohmann than we have, and they know the decision-makers betUniversity Hospital's
decision. He wanted to apply the ter than we do. But we are learning fast." Sigma, the lessons
from this experience to future sales situations. subsidiary of a diversified Dutch company under
the same name, was the company's most serious competiBACKGROUND tor. Other major
contenders in the CT scanner market were FNC, Eldora, Magna, and Piper. At the time, the
computer tomography (CT) scanner Mediquip executives estimated the European marwas a
relatively recent product in the field of diagnostic ket for CT scanners to be around 200 units per
year. imaging. This medical device, used for diagnostic pur- They pointed out that prices ranged
from 1.5 to 3.0 poses, allowed examination of cross sections of the million per unit. The
company's CT scanner sold in the human body through display of images. CT scanners upper
end of the price range. "Our equipment is at least combined sophisticated X-ray equipment with
a com- two years ahead of our most advanced competition," puter to collect the necessary data
and translate them explained a sales executive. "And our price reflects this into visual images.
When computer tomography was first introduced in Mediquip's sales organization in Europe
included the late 1960s, radiologists had hailed it as a major tech- eight country sales
subsidiaries, each headed by a mannologiqal breakthrough. Commenting on the adva.
Methanex is the world's largest producer and supplier of methanol. We create value through our leadership in the global production, marketing and delivery of methanol to customers. View our latest Investor Presentation for more details.
X Sector Disruption | CIO Leaders Summit 2015 | The Propell GroupJulien de Salaberry
- Technology is or will disrupt your sector
- Hoping that it might miss you out is not a strategy!
- You will need to embrace and adopt the technology to innovate to stay in the game
- You also have the opportunity to explore how technology could enable your industry to disrupt another
The document discusses go-to-market strategies for product engineering services in the orthopedics sector. It provides an overview of the large and growing global orthopedics market and outsourcing industry. It then outlines the primary factors driving demand for consulting product engineering services in orthopedics. Some key opportunities identified include implant designing, orthopedics PACS systems, medical devices, software applications, product validation, and operating room solutions. The document recommends starting with orthopedics PACS to enter the market and also partnering with large western companies to bring navigation technologies to India.
The team conducted over 100 interviews with surgeons, radiologists, administrators and other stakeholders. Based on feedback, they pivoted their focus from urology to thoracic surgery. Thoracic surgeons expressed a strong need for a product that could help localize lung lesions minimally invasively. The team determined thoracic surgery represents a $250 million market opportunity in the US. They have refined their product and business model based on learning that thoracic surgeons could find small lung nodules twice as fast with the technology without need for preoperative preparation. The team believes they will pursue an SBIR Phase II application with a significant pivot in customer segments from original plans but that the technical feasibility remains.
Caduceus Medical Corp is developing non-invasive devices to monitor intraocular pressure and treat glaucoma and other eye conditions. Their first product, the IOP Sensor, continuously measures intraocular pressure over time to aid in earlier diagnosis and treatment. They have filed patents and plan to market to ophthalmologists and optometrists in the US initially. The management team has extensive experience in ophthalmic devices. They are seeking $14 million to complete development and clinical trials and launch the product.
With Piezomed, users can concentrate on the surgical procedure with a piece o...A-dec Australia
W&H's Piezomed device utilizes innovative ultrasound technology to facilitate precise and minimally invasive bone cutting for dental surgeons. It was developed to complement their existing surgical product range and addresses the need for a piezoelectric device. Significant research was required to develop it given the demanding precision required. The automatic instrument detection system and ability to precisely cut bone make it useful for a variety of dental procedures.
RD Medical is a company that designs and manufactures spinal fixation systems and implants. It was founded by mechanical and materials engineers, along with clinical experts. The company supplies innovative, high-quality products to the biomedical industry as an OEM partner. PRODORTH products are designed, manufactured, and developed in-house. The company aims to provide top-notch, detailed products to contribute to successful surgeries and patient outcomes. It works to satisfy the need for high-quality, fast-supplied products in the medical sector.
This document provides a business plan for SeamVad, a medical device company developing automated vascular anastomosis devices. SeamVad's flagship product, the MySide device, uses a connector and applicator to perform vessel anastomoses in a simple 6-step process, reducing time compared to manual suturing. The $3 billion global vascular devices market is poised for growth. SeamVad seeks $3 million in funding to complete clinical trials and gain CE Mark approval by 2014. The management team has extensive experience in vascular surgery and medical devices. The plan outlines SeamVad's product, the clinical need it addresses, competitive landscape, and financial projections.
Capsule Endoscopy Patent Landscape 2014 Sample
Olympus and Given Imaging are leading intellectual property in the capsule endoscopy industry, but for how long?
KEY FEATURES OF THE REPORT
The report provides essential patent data for capsule endoscopy. It identifies more than 30 major holders of capsule endoscopy related intellectual property. It provides in-depth IP analysis and industrial key players including:
-Time evolution of patent publications and countries of patent filings.
-Current legal status of patents.
-Ranking of main patent applicants.
-Joint developments and IP collaboration network of main patent applicants.
-Key patents.
-Granted patents near expiration.
-Relative strength of main companies IP portfolio.
-Overview of patent litigations.
-Matrix applicants/technology issues for more than 15+ companies.
The “capsule endoscopy IP” profiles of 15+ major companies is presented, with key patents, technological issues, litigations, licenses, partnerships, and IP strength and strategy.
The report also provides an extensive Excel database with all patents analyzed in the report.
OBJECTIVE OF THE REPORT
•Understand the IP landscape for capsule endoscopy.
•Identify key patents.
•Understand trends in capsule endoscopy IP.
•Identify the major players in capsule endoscopy IP and the relative strength of their patent portfolio.
•Identify new players in capsule endoscopy IP.
•Identify IP collaboration networks between key players (industrial and academics).
•Identify main patent litigations.
Top 5 Trends from RSNA 2015 Day 1 | MD BuylineMD Buyline
Day 1 of RSNA 2015: Learn what the top trends were at the Radiological Society of North America (RSNA) annual meeting and scientific assembly for 2015; from the leader in healthcare supply chain management solutions, MD Buyline.
For the full article, visit http://www.mdbuyline.com/research-library/articles/top-5-trends-from-rsna-2015-day-1/.
Europe’s Most Innovative Medical Device Companies of 2023 (Bleed) 2 (1).pdfinsightscare
This article profiles Morpheus AG, a medical device company focused on developing innovative surgical instruments. The company's flagship product is the Rebellion Bone Removal System, which allows surgeons to efficiently cut through bone while minimizing risks. Morpheus AG is dedicated to designing technologies that maximize safety, efficiency and effectiveness in the operating room. The company prioritizes innovation, quality and patient safety in its work. It aims to develop solutions that can help healthcare professionals and improve patient outcomes.
Capsule Endoscopy Patent Landscape Flyer 2014
Olympus and Given Imaging are leading intellectual property in the capsule endoscopy industry, but for how long?
KEY FEATURES OF THE REPORT
The report provides essential patent data for capsule endoscopy. It identifies more than 30 major holders of capsule endoscopy related intellectual property. It provides in-depth IP analysis and industrial key players including:
-Time evolution of patent publications and countries of patent filings.
-Current legal status of patents.
-Ranking of main patent applicants.
-Joint developments and IP collaboration network of main patent applicants.
-Key patents.
-Granted patents near expiration.
-Relative strength of main companies IP portfolio.
-Overview of patent litigations.
-Matrix applicants/technology issues for more than 15+ companies.
The “capsule endoscopy IP” profiles of 15+ major companies is presented, with key patents, technological issues, litigations, licenses, partnerships, and IP strength and strategy.
The report also provides an extensive Excel database with all patents analyzed in the report.
OBJECTIVE OF THE REPORT
•Understand the IP landscape for capsule endoscopy.
•Identify key patents.
•Understand trends in capsule endoscopy IP.
•Identify the major players in capsule
endoscopy IP and the relative strength of
their patent portfolio.
•Identify new players in capsule endoscopy IP.
•Identify IP collaboration networks between key players (industrial and academics).
•Identify main patent litigations.
Medvantage International has acquired rights to a new vascular coupling device called CUVASLAR that represents an alternative to manual suturing for connecting arteries and veins. The device is expected to reduce surgical time, minimize errors from suturing, and improve patient outcomes. Medvantage plans to submit the device for FDA approval over the next year and market it to the 340,000 microsurgery procedures performed annually in the US.
Anteo Technologies - New York presentation 2015Matt Sanderson
- Anteo Diagnostics is an Australian biotechnology company that develops proprietary surface coatings called Mix&Go for use in healthcare, life sciences, and other industries.
- Mix&Go is a universal double-sided molecular coating that gently but strongly binds biomolecules to synthetic surfaces, addressing challenges in test miniaturization and cost reduction.
- Anteo's growth strategy includes licensing its intellectual property, expanding its coating technologies and applications, developing product pipelines that demonstrate Mix&Go's uses, exploring new market opportunities, and acquiring synergistic assets.
Ultrasound Sensing Technologies for Medical, Industrial and Consumer Applicat...Yole Developpement
New applications along with manufacturing capabilities and technological readiness are driving the takeoff of micro-machined ultrasonic transducers.
More information on that report at https://www.i-micronews.com/category-listing/product/ultrasound-sensing-technologies-for-medical-industrial-and-consumer-applications.html
1) Terumo Corporation developed the world's thinnest insulin injection needle called the Nanopass 33 needle in collaboration with Okano company.
2) Terumo obtained patent protection for the needle's slim double tapered shape and asymmetric bevel which reduces pain during injections.
3) Terumo also registered its company trademark to protect its brand and product names.
Michael Alvers, Transinsight, DE (Fortissimo)I4MS_eu
The document discusses using high-performance computing (HPC) for drug-target binding simulations. It describes how HPC resources from the Fortissimo project enable performing over 450 million pairwise molecule-ligand comparisons, allowing for novel drug target prediction, side effect prediction, and drug repositioning. Two universities implemented and optimized distributed algorithms to run the drug binding simulations on HPC infrastructure 5-10 times faster. This provides a framework for previously impossible bioinformatics analyses to discover new drugs.
An NGO called mothers2mothers (m2m) recruits and trains HIV-positive mothers to provide support to other mothers living with HIV/AIDS. m2m has expanded across Africa and helps prevent mother-to-child transmission of HIV. The organization protects its brand identity through trademarks on its name and logo, which help promote public awareness and fundraising efforts. Trademarks provide affordable intellectual property protection that supports m2m's work in building its reputation.
This document provides background information for developing a launch plan for Monocryl Plus, a new antibacterial coated synthetic absorbable suture. It discusses the suture market challenges facing Ethicon, including increased competition from low-cost producers. It also reviews the product details and performance of existing sutures like Vicryl and Monocryl. The consultant has been asked to develop a strategic launch plan for Monocryl Plus to drive adoption among surgeons and in new applications/markets.
How well did Thaldorf interact with each member of the DMUOn what.pdfallystraders
How well did Thaldorf interact with each member of the DMU?
On what date did Thaldorf effectively lose the sale to Lohmann University? On December 18,
Kurt Thaldorf, a sales engineer for can diagnose cancer of the pancreas in less than two the
German sales subsidiary of Mediquip, S.A., was weeks after it develops. This was not possible
before informed by Lohmann University Hospital in Stuttgart CT scanners." that it had decided
to place an order with Sigma, a Mediquip was a subsidiary of Technologie UniDutch competitor,
for a CT scanner. The hospital's verselle, a French conglomerate. The company's proddecision
came as disappointing news to Thaldorf, who uct line included, in addition to CT scanners, X-
ray, had worked for nearly eight months on the account. ultrasonic, and nuclear diagnostic
equipment. Mediquip The order, if obtained, would have meant a sale of enjoyed a worldwide
reputation for advanced technol(Euro) 2,370,000 for the sales engineer. 1 He was con- ogy and
competent after-sales service. vinced that Mediquip's CTscanner was technologically "Our
competitors are mostly from other European superior to Sigma's and, overall, a better product.
countries," commented Mediquip's Sales Director for Thaldorf began a review of his call reports
in order Europe. "In some markets they have been there longer to better understand the factors
that had led to Lohmann than we have, and they know the decision-makers betUniversity
Hospital's decision. He wanted to apply the ter than we do. But we are learning fast." Sigma, the
lessons from this experience to future sales situations. subsidiary of a diversified Dutch company
under the same name, was the company's most serious competiBACKGROUND tor. Other
major contenders in the CT scanner market were FNC, Eldora, Magna, and Piper. At the time,
the computer tomography (CT) scanner Mediquip executives estimated the European marwas a
relatively recent product in the field of diagnostic ket for CT scanners to be around 200 units per
year. imaging. This medical device, used for diagnostic pur- They pointed out that prices ranged
from 1.5 to 3.0 poses, allowed examination of cross sections of the million per unit. The
company's CT scanner sold in the human body through display of images. CT scanners upper
end of the price range. "Our equipment is at least combined sophisticated X-ray equipment with
a com- two years ahead of our most advanced competition," puter to collect the necessary data
and translate them explained a sales executive. "And our price reflects this into visual images.
When computer tomography was first introduced in Mediquip's sales organization in Europe
included the late 1960s, radiologists had hailed it as a major tech- eight country sales
subsidiaries, each headed by a mannologiqal breakthrough. Commenting on the advantages
aging director. Within each country, sales engineers of CT scanners, a product specialist with
Mediquip said, reported to regional sales managers who, in turn, ".
Going into this situation, what were Thaldorf�s major strengths and .pdfaucmistry
Going into this situation, what were Thaldorfs major strengths and weaknesses as a
representative of Mediquip?
Identify each member of Lohmann Hospitals decision-making unit (DMU).
What were the needs, concerns, and motivation of each DMU member?
What was the relative power position of each DMU member? On December 18, Kurt Thaldorf, a
sales engineer for can diagnose cancer of the pancreas in less than two the German sales
subsidiary of Mediquip, S.A., was weeks after it develops. This was not possible before informed
by Lohmann University Hospital in Stuttgart CT scanners." that it had decided to place an order
with Sigma, a Mediquip was a subsidiary of Technologie UniDutch competitor, for a CT
scanner. The hospital's verselle, a French conglomerate. The company's proddecision came as
disappointing news to Thaldorf, who uct line included, in addition to CT scanners, X-ray, had
worked for nearly eight months on the account. ultrasonic, and nuclear diagnostic equipment.
Mediquip The order, if obtained, would have meant a sale of enjoyed a worldwide reputation for
advanced technol(Euro) 2,370,000 for the sales engineer. 1 He was con- ogy and competent
after-sales service. vinced that Mediquip's CTscanner was technologically "Our competitors are
mostly from other European superior to Sigma's and, overall, a better product. countries,"
commented Mediquip's Sales Director for Thaldorf began a review of his call reports in order
Europe. "In some markets they have been there longer to better understand the factors that had
led to Lohmann than we have, and they know the decision-makers betUniversity Hospital's
decision. He wanted to apply the ter than we do. But we are learning fast." Sigma, the lessons
from this experience to future sales situations. subsidiary of a diversified Dutch company under
the same name, was the company's most serious competiBACKGROUND tor. Other major
contenders in the CT scanner market were FNC, Eldora, Magna, and Piper. At the time, the
computer tomography (CT) scanner Mediquip executives estimated the European marwas a
relatively recent product in the field of diagnostic ket for CT scanners to be around 200 units per
year. imaging. This medical device, used for diagnostic pur- They pointed out that prices ranged
from 1.5 to 3.0 poses, allowed examination of cross sections of the million per unit. The
company's CT scanner sold in the human body through display of images. CT scanners upper
end of the price range. "Our equipment is at least combined sophisticated X-ray equipment with
a com- two years ahead of our most advanced competition," puter to collect the necessary data
and translate them explained a sales executive. "And our price reflects this into visual images.
When computer tomography was first introduced in Mediquip's sales organization in Europe
included the late 1960s, radiologists had hailed it as a major tech- eight country sales
subsidiaries, each headed by a mannologiqal breakthrough. Commenting on the adva.
Similar to Surge-on Medical - Pitch Deck 2019 (20)
Methanex is the world's largest producer and supplier of methanol. We create value through our leadership in the global production, marketing and delivery of methanol to customers. View our latest Investor Presentation for more details.
UnityNet World Environment Day Abraham Project 2024 Press ReleaseLHelferty
June 12, 2024 UnityNet International (#UNI) World Environment Day Abraham Project 2024 Press Release from Markham / Mississauga, Ontario in the, Greater Tkaronto Bioregion, Canada in the North American Great Lakes Watersheds of North America (Turtle Island).
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4study presented by a Big 4
Cleades Robinson, a respected leader in Philadelphia's police force, is known for his diplomatic and tactful approach, fostering a strong community rapport.
The E-Way Bill revolutionizes logistics by digitizing the documentation of goods transport, ensuring transparency, tax compliance, and streamlined processes. This mandatory, electronic system reduces delays, enhances accountability, and combats tax evasion, benefiting businesses and authorities alike. Embrace the E-Way Bill for efficient, reliable transportation operations.
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdfSOFTTECHHUB
The world of blockchain and decentralized technologies is about to witness a groundbreaking event. ZKsync, the pioneering Ethereum Layer 2 network, has announced the highly anticipated airdrop of its native token, ZK. This move marks a significant milestone in the protocol's journey, empowering the community to take the reins and shape the future of this revolutionary ecosystem.
2. About us
At Surge-on Medical, we are convinced
that surgeons can do more than current
instruments allow. With this in mind, we have
developed the next generation of minimally
invasive surgical instruments. Through our
cable-free platform technology, we created
freedimensional instruments that provide
better access to surgical areas and replace
current pre- bent instrumentation.
≈
3. Our solution
From multiple pre – bent instruments Towards an ergonomic single instrument with adjustable tip angle
Our first product is the Steerable Punch
it offers the needed extra reachability in joints, and prevents the use of multiple cutting instruments.
With the Steerable Punch, surgeons can
perform arthroscopic knee surgery with just
one instrument, as they can now steer the tip
in the joint independently from its location.
Our freedimensional instruments offer cable-
free steerability with up to 80% fewer parts.
4. Problem
Surgeons often struggle with gaining access to the surgical
site, as well as with the alignment of the instrument tip for
manipulation, suturing, or cutting of the tissues:
Decreased reachability causes high forces
on the incisions and in internal tissues.
Poor instrument alignment increases the
procedure time as surgeons need to interrupt
their workflow to find the right instrument.
Rigid instruments force the surgeon to stand in
unergonomic postures, apply force and cause
hand injuries.
Multiple pre-bent tools required per surgery
increase the costs for the hospitals: instruments
and cleaning costs.
5. Patent position
*2 patents exclusive, permanent license TU Delft + 2 patents full ownership.
4 international patents* on the cable-less steering mechanism,
detachability and coupling mechanism, and practical applications.
In addition, two of our patents hold specific aims about the
methods used to connect nitinol to stainless steel, transmission
ratio between rotation and articulation that depends on the
angle and shape of cut-outs in the tube, a unique way to protect
the instruments against overloading, and a method to replace the
shaft in a few seconds, due to its patented modular design.
All patents applied for or granted in European Union; China,
South Korea and/or Japan; and United States.
The patents are public under the reference numbers: WO2018106116,
WO2018074919, WO2014148898 and WO2016111621.
The coherence and strength of the 4 patents make it very difficult to
copy and iterate (read: ‘work around’) on one of the unique
aspects without interfering with the other claims.
6. Platform technology
Our patent portfolio gives the potential to replace all minimally invasive instruments that are on the market today with
our steerable, detachable, cleanable technology.
Steerable Punch
market-ready; for arthroscopy
Steerable Grasper
prototype: expected late 2020
market-ready; for laparoscopy
PoLaRS
robotic training: early prototype;
full portable robot: proof of concept
Current products
Arthroscopy Laparoscopy Modular robotics
7. Addressable market size
(1) Using on average 4.4 instruments per surgery; (2) Global Data 2013; (3) Allied Market Research 2017; (4) Global Data 2016, not including China and Russia; (5) Grand View Research 2018.
€273 M €1.8 billion €3.2 billion
Steerable Punch Steerable Grasper PoLaRS
Arthroscopy Laparoscopy Robotic Surgery
Meniscal Punches (all)
€601 M (1)
World: 4.1 M
meniscectomies (2)
€7.6 billion (3) €3.6 billion (5)
Instrumentation (all)
World: 35 M
laparoscopies (4)
Surgical robots
All surgical areas
This market size did not positively affect the
prospectus company valuation, because
sales are expected after the financial
forecast period.
8. Competition
Some of the worldwide established competitors in the
fields of arthroscopy and laparoscopy are Smith &
Nephew, Stryker, Arthrex, ConMed, DePuy Synthes,
B.Braun, and Storz.
Finding an alternative for a stiff and steerable tip that has a
small bending radius, combined with detachability and
cleanability, other than our multi-patented technologies, has
proven extremely difficult. Our intellectual property rights
can prevent other companies to copy our inventions.
With our intellectual property, potentially most of the
minimally invasive surgical instruments (currently on the
market) can be made steerable and detachable, which
can increase the market size numbers in the future
9. Competitive advantage
* For arthroscopy there are no steerable alternatives on the market, for laparoscopy there are.
Same principles for the Steerable Punch and Steerable Grasper compared to the competition. The
combination of all the above is unique and multi-patented by us, making our technology very cost-effective
(lower total price per surgery) and improving the usability of the instrument by the surgeon.
Strong
Detachable
Cable-free
Economic cleaning
Steerable
Disposable
instruments
Reusable
instruments
*
10. Business model and traction
The countries listed reflect historical sales and contracts.
Product sales will be direct and through international distributors, starting in
Europe and Asia.
After FDA approval, the USA will follow for product sales
Product
sales
Contract
research
IP licenses
11. Sales and manufacturing
The Steerable Punch sales price of EUR2500 (end-user) has been
tested and is accepted by the market by multiple sales.
The Steerable Punch is manufactured by experienced ISO13485
medical manufacturers. This will be the case for our new
products too.
Distributors in multiple countries in Europe, China, South
Korea, Costa Rica, Turkey, South Africa, and counting, have
shown interest and are ready to sign distribution contracts.
Surgeon Medical is currently working with distributors and end-
users to match pre-orders with larger scale manufacturing
capacity in the Netherlands and Germany
The triple digit markup percentage shall improve even more over
time, by positive scaling effects.
12. Regulatory Steerable Punch
CE (Europe) MFDS (South Korea) FDA (US)
Class 1r, under the new EU
regulation MDR 2017/745
In preparation towards the
regulatory switch on May 2020,
Surge-on Medical has started
to arrange the required
documentation and the set-up
of the quality system.
As an extra: the Dutch
Ministry of Health has given
permission to start the
clinical investigation
surgeries from now on.
Known as Korean FDA
NIDS Certification
granted, as a class I
device.
The Steerable Punch has
been sold and will used for
surgeries in South Korea.
510(K)exempt
FDA certification process
starts after CE will be
granted.
13. Traction
FUNDING
ANDMARKET Since 2015 more than EUR 650,000 funding
from grants, angel investor, bank loans
and award money.
Pre-market launch revenue by contract
research for US, and Steerable Punch
demo batch sold in China, South Korea
and the Netherlands.
AWARDS
Top 3 European med tech startups
elected by EIT Health Catapult 2017.
“Most innovative product” award
Pharma Trend 2019.
Tim Horeman (CTO), Dutch
Engineer of the Year 2016.
14. Exits & acquisitions in our market
The acquisitions below are in fields where Surge-on Medical is already active, or will be
active due to the increasing product line based on our multi-patented platform technology.
This gives an indication for the exit potential in the future.
Ceterix Orthopedics
Arthroscopy, meniscal repair, single product.
“The cost of the acquisition is $50 million and up
to a further $55 million over the next five years.”
Corindus vascular robotics
Surgery robots, laparoscopy. “For $1.1 billion
acquired by Siemens Healthineers. An impressive
amount, given that Corindus generates annual
revenue of approx. 11 million US dollars and
makes a loss of 35 million US dollars.”
Entellus Medical Inc
ENT surgery. “Stryker Corporation acquired Entellus
in an all cash transaction with an equity value of
approximately $662 million.”
Cayenne Medical
Arthroscopy. “Sources say that Zimmer will pay
$150M in total earnouts on $20M sales by cayenne
in the last year.”
NuVasive
Arthroscopy (hip and knee). “Smith & nephew to buy
Nuvasive in a deal that would be worth more than $3
billion.” Exit not completed, for indication only.
15. Plus: Elite test team with 11 surgeons from 10 hospitals.
Management Team Advisors
Benno Groosman MScBA
12 years medtech entrepreneur
CEO & Founder
Dr.ir Tim Horeman, PhD
Ass.prof. TU Delft, 11 years entrepreneur
CTO & Founder
Audry Zoncsich MSc
MSc chemistry, project management
COO
Prof.dr. Gino Kerkhoffs
Head elite test team
Active orthopedic surgeon
Dr.ir. Gabrielle Tuijthof, PhD
Head of clinical studies
Researcher multiple universities
Dr. Wenjing Ding MD, Sc.D
International sales
Surgeon, investor, US/China
18. Disclaimer / Imprint
This document is a customer information ("CI") within the meaning of the German Securities Trading Act, the "CI" is intended for natural and
legal persons with a habitual residence or registered office in Germany and is used exclusively for information purposes.
This "CI" cannot replace individual investment and investor-oriented advice and does not constitute a contract or any other obligation or any
kind of contractual offer. Furthermore, the contents do not constitute investment advice, an individual investment recommendation, an
invitation to subscribe to securities or a declaration of intent or invitation to conclude a contract for a transaction in financial instruments. Nor
was it written with the intention of providing legal or tax advice. The tax treatment of transactions depends on the personal circumstances of
the respective client and may be subject to future changes. The individual circumstances of the recipient (including the economic and
financial situation) were not taken into account in the preparation of the "CI".
An investment in the aforementioned financial instruments/investment strategy/financial services involves certain product-specific risks – e.g.
market or sector risks, currency, default, liquidity, interest rate and credit risk – and is not suitable for all investors. Therefore, potential investors
should only make an investment decision after a detailed investment consultation with a registered investment advisor and after consulting all
available sources of information. For further information, you will find the "Essential Investor Information" and the securities prospectus here:
www.aescuvest.eu
Past performance is not a reliable indicator of future performance. Recommendations and forecasts represent non-binding value judgements
about future events and may therefore prove to be incorrect with regard to the future development of a product. The listed information refers
exclusively to the time of the production of this "AI", a guarantee for the topicality and continuing correctness cannot be given. The
information provided refers exclusively to the time of preparation of this "CI", no guarantee can be given that it is up to date and continues to
be correct.
The above content exclusively reflects the opinions of the author; a change of these opinions is possible at any time without publication. The
present "CI" is protected by copyright, any duplication and commercial use is not permitted. Date: 20th October 2019
Publisher: Aescuvest international GmbH, Hanauer Landstr. 328-330, 60314 Frankfurt am Main is acting as a contractually bound agent (§2
section 10 KWG) on behalf, in the name, for the account and under the liability of the responsible liable party BN & Partners Capital AG,
Steinstrasse 33, 50374 Erftstadt. BN & Partners Capital AG holds a corresponding license from the Federal Financial Supervisory Authority
(Bundesanstalt für Finanzdienstleistungsaufsicht) pursuant to section §32 of the KWG for the provision of investment advice pursuant to §1
section 1a no.1 of the KWG and investment brokerage pursuant to section §1 section 1a no. 1a of the KWG.